Clinical Trial Update: A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 translational and neurocomputational evaluation of a dopamine D1 receptor partial agonist for schizophrenia has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• D1 receptor partial agonist (experimental)

Snippet

Sponsor: Yale University | Conditions: Early Course Schizophrenia Spectrum Disorder | Phase 2 | Status: COMPLETED | Results posted: 2025-10-15